# Eli Lilly invests $450M in North Carolina plant for diabetes drugs

Eli Lilly will invest $450 million in its Research Triangle Park, North Carolina manufacturing plant to expand filling, device assembly and packaging capacity for diabetes drugs Mounjaro and Trulicity. The investment aims to double production by end of 2023 and add 100 jobs. The new phase will be completed in 2027.

- Type: Investment
- Announced: 2023-02-01
- Where: Research Triangle Park, North Carolina, United States
- Value: $450.0M
- Jobs: 100
- Starts operating: 2027
- Status: announced
- Capacity: double production of injectable drugs
- Products: Mounjaro, Trulicity, injectable diabetes drugs
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Eli Lilly](https://endata.com/companies/32564.md)

## Sources

- [manufacturingdive.com](https://www.manufacturingdive.com/news/lilly-450-million-manufacturing-north-carolina-incretin/641221/), 2023-02-01: "The investment in the Research Triangle Park plant will expand filling, device assembly and packaging capacity to help the Indiana-based drugmaker double production of the injectable drugs by the end of 2023."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.